KMT2D抗体—艾普蒂

+ +

•  

   

     Western blot analysis of lysate from Hela cell line, using DDX6 Antibody (C-term)(Cat. #P31724). P31724 was diluted at 1:1000 at each lane. A goat anti-rabbit IgG H&L(HRP) at 1:5000 dilution was used as the secondary antibody. Lysate at 35ug per lane.    

  
  

The KMT2D antibody is a crucial tool for studying the KMT2D gene (lysine methyltransferase 2D), which encodes a histone methyltransferase involved in epigenetic regulation. KMT2D, also known as MLL4. belongs to the COMPASS family and catalyzes mono- and di-methylation of histone H3 on lysine 4 (H3K4), a modification linked to active gene transcription. Mutations in KMT2D are associated with developmental disorders like Kabuki syndrome and various cancers, including lymphoma, breast cancer, and colorectal carcinoma, underscoring its role in cell differentiation, proliferation, and tumor suppression.

KMT2D antibodies are widely used in research to detect protein expression, localization, and interactions in tissues or cell lines. They enable techniques like Western blotting, immunohistochemistry (IHC), chromatin immunoprecipitation (ChIP), and immunofluorescence (IF) to explore KMT2D’s involvement in chromatin remodeling, transcriptional regulation, and disease mechanisms. These antibodies also help identify aberrant KMT2D expression or post-translational modifications in pathological contexts.

Quality validation of KMT2D antibodies is critical due to the protein’s large size (~550 kDa) and structural complexity. Researchers prioritize antibodies with high specificity, verified through knockout controls or siRNA knockdown. Commercial KMT2D antibodies vary in clonality (monoclonal/polyclonal) and epitope targets, requiring careful selection based on experimental needs. Their applications span basic epigenetics, cancer biology, and therapeutic development, particularly in studying KMT2D-related dysregulation and potential targeted therapies.